Team:
We are excited to share that the preprint for the study “Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study” has been posted in medRxiv.
Harlan Krumholz wrote a blog about our preprint in Forbes Health, which you can find here.
Thank you to everybody who collaborated on this study. Please remember that these are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
An OHDSI press release on this preprint is now posted on our COVID-19 updates page.
